News | May 27, 2023
Sun Pharmaceutical Industries posts Q4 FY23 consolidated PAT at Rs. 2016.78 Cr
The company has reported total income of Rs. 11303.95 crores during the period ended March 31, 2023
The company has reported total income of Rs. 11303.95 crores during the period ended March 31, 2023
The company has reported total income of Rs. 3276.35 crores during the period ended March 31, 2023
The company has reported total income of Rs. 880.59 crores during the period ended March 31, 2023
For Q4 ended FY23, company reported net profit of Rs. 12.56 crore as against net profit of Rs. 11.02 crore in the corresponding period last year
The Global Medical Countermeasures Platform will provide equal access safe, high-quality, cost-effective medical countermeasures to the world
The company has reported total income of Rs. 2188.08 crores during the period ended March 31, 2023
Operating EBITDA increased by 21% to INR 181 crores in Q4 FY23
The drug discovery of mRNA-targeted small molecules is rapidly gaining attention due to the current difficulty of developing drugs against conventional protein targets
Lonza launches the TheraPEAK T-VIVO Cell Culture Medium with a novel chemically defined formulation developed to optimize and streamline CAR T-cell manufacturing
5C Network’s groundbreaking platform aims to bring together diagnostic facilities and healthcare aggregators on a single platform to deliver an unparalleled patient experience
Subscribe To Our Newsletter & Stay Updated
